Key Highlights

  • The Supreme Court declined to hear appeals from Novo Nordisk, AstraZeneca and four other drugmakers against Medicare price talks.
  • The programme, created by the Inflation Reduction Act (IRA), is projected to save the federal government $160bn over a decade.
  • Medicare’s first round of negotiations—covering ten drugs—saved the programme $5bn in its inaugural year, per CMS data.
  • Industry lobby groups warn the precedent could chill innovation; investors pushed down pharma equities by 1.4% the day after the ruling.
  • The decision leaves intact lower-court rulings and keeps the programme on track to add more drugs to negotiation lists by 2027 and 2029.

A landmark ruling with deep implications

The Supreme Court’s refusal to hear appeals from Novo Nordisk, AstraZeneca (LSE: AZN), Bristol-Myers Squibb Company (NYSE: BMY), Johnson &Amp; Johnson (NYSE: JNJ), Merck & Co Inc. (NYSE: MRK) and Boehringer Ingelheim signals the end of Big Pharma’s legal campaign against the Inflation Reduction Act’s (IRA) Medicare drug-price negotiation programme. The court’s move upholds lower-court decisions that found the programme constitutional; the justices’ decision not to grant certiorari preserves a policy that will reshape pricing dynamics across the $600bn U.S. prescription-drug market. Analysts at SVB Securities estimate the policy could shave 3-5% off peak sales for the ten drugs selected in 2026—among them Eliquis (Pfizer Inc. (NYSE: PFE)/BMS) and Jardiance (Boehringer/Eli Lilly (NYSE: LLY))—and potentially extend to dozens more by the decade’s end. The ruling arrives as President Donald Trump pushes new “Most Favoured Nation” policies that would peg U.S. drug prices to lower foreign benchmarks, adding another layer of pricing pressure.

The Economics behind the policy

The IRA’s negotiation mandate, which applies only to drugs without generic or biosimilar competition, is projected to deliver $160bn in federal savings between 2026 and 2035, according to the Congressional Budget Office. In its first year alone, the Centres for Medicare & Medicaid Services (CMS) reported $5bn in net savings after accounting for rebates and discounts secured through the programme. The drugs selected—ranging from diabetes treatments to blood thinners—accounted for roughly 20% of total Medicare Part D spending in 2023. Industry data from IQVIA show that these therapies generated combined U.S. revenues of $54bn that year; under the IRA framework, manufacturers must offer discounts of up to 60% off list prices for some products by 2032. The policy’s phased implementation—10 drugs in 2026, 15 in 2027 and 20 in 2029—gives companies limited time to adjust pricing strategies and portfolio allocations.

Industry pushback and strategic pivots

Pharma’s legal challenge rested on two pillars: constitutional objections to government-imposed price controls and claims that the programme would stifle R&D Investment. The Pharmaceutical Research and Manufacturers of America (PhRMA) argued that the policy violated the Fifth Amendment’s Takings Clause by compelling companies to sell at below-market prices. Yet the Supreme Court’s denial of review suggests the justices saw no merit in these constitutional arguments—a view echoed by the United States Court of Appeals for the District of Columbia Circuit, which upheld the programme in February. In response, several companies have already recalibrated their pipelines: Eli Lilly revealed plans to accelerate development of obesity drugs with higher price flexibility, while Novo Nordisk (CPH: NOVO-B) is shifting resources toward early-stage Assets in cardiometabolic and rare diseases. Investor sentiment, however, remains cautious; the S&P 500 Pharmaceuticals index fell 1.4% on the day of the ruling, with Johnson & Johnson (NYSE: JNJ) and Merck (NYSE: MRK) among the hardest hit.

Political cross-currents and the Trump Factor

The Supreme Court’s decision lands amid a shifting political landscape: President Trump has signalled his intent to roll back the IRA’s negotiation framework through executive action, while simultaneously pursuing “Most Favoured Nation” policies that would tie U.S. prices to lower prices in Canada, Germany and Japan. The White House estimates the latter could save another $15bn annually, though critics argue it risks Supply shortages and reduced access to novel therapies. Meanwhile, Democratic lawmakers—including Senate Majority Leader Chuck Schumer—have framed the Supreme Court’s move as a victory for fiscal responsibility and patient affordability. The policy’s durability now hinges on whether the next administration can unwind it administratively or through Congress. Analysts at Guggenheim Partners note that even a partial rollback would face legal hurdles, given the programme’s statutory underpinnings and the Supreme Court’s deference to agency rulemaking in recent rulings such as *Chevron*.

Broader market and geopolitical ripple effects

The ruling’s immediate impact extends beyond U.S. shores: European regulators, who have long chafed at high drug prices, may see the IRA as a model for their own pricing reforms. Conversely, global pharma executives warn that the policy could slow the introduction of breakthrough therapies in the U.S. market—a concern highlighted by a 2024 survey from the Tufts Center for the Study of Drug Development, which found that 42% of biotech firms planned to delay or cancel U.S. launches for certain drugs. The decision also complicates Merger-and-Acquisition strategies: Pfizer’s (NYSE: PFE) $43bn acquisition of Seagen in 2023 was partly justified by the expectation of premium pricing for oncology drugs; under the IRA, such calculations may need revision. Longer term, the policy could accelerate the shift toward value-based contracting, where drugmakers tie reimbursement to patient outcomes rather than units sold—a model already gaining traction in Europe.